Direct Answer
Johnson & Johnson was founded in 1886 in New Brunswick, New Jersey, by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson. The company was incorporated in New Jersey in 1887 to manufacture sterile surgical dressings, and completed its NYSE IPO on September 24, 1944, under the ticker JNJ. Over the following eight decades, J&J expanded through acquisitions including McNeil Laboratories (Tylenol, 1959), Janssen Pharmaceutica (1961), and Synthes (2011). The 1982 Tylenol tampering crisis, in which J&J recalled 31 million bottles, became a widely taught crisis management case study. In May 2023, J&J spun off its consumer health segment as Kenvue, retaining its pharmaceutical and medical device businesses.
Founding and early years
Johnson & Johnson was founded in 1886 in New Brunswick, New Jersey, by Robert Wood Johnson I and his brothers James Wood Johnson and Edward Mead Johnson. The company was inspired by British surgeon Joseph Lister's germ theory of infection, which had established that bacteria caused post-surgical complications. J&J set out to manufacture sterile surgical dressings and antiseptic products at a time when most wound care products were not produced under sanitary conditions.
The company was incorporated in New Jersey in 1887. In 1888, J&J published "Modern Methods of Antiseptic Wound Treatment," a medical text distributed free to physicians across the United States, establishing an early relationship with the medical profession built on education rather than direct sales alone. The company introduced its baby powder product in 1894, and in 1921 an employee named Earle Dickson invented Band-Aid adhesive bandages as a ready-made wound care solution for his wife, who frequently cut herself while cooking. The Band-Aid product became one of the company's most enduring consumer brands.
Robert Wood Johnson II became chairman in 1932 and established the decentralized management model that continues to define J&J's operating structure, with individual business units operating with significant autonomy within the broader company. In 1943, the year before J&J's NYSE listing, Johnson II wrote "Our Credo," a statement of corporate values placing responsibility to patients, consumers, employees, and communities ahead of responsibility to stockholders. The Credo is credited with shaping management decisions throughout the company's history, including during the 1982 Tylenol crisis.
Key milestones
| Date | Event |
|---|---|
| 1886 | Company founded in New Brunswick, New Jersey, by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson |
| 1887 | Incorporated in New Jersey; begins manufacturing sterile surgical dressings and antiseptic products |
| 1888 | Published "Modern Methods of Antiseptic Wound Treatment," distributed free to physicians |
| 1894 | Baby powder product introduced |
| 1921 | Band-Aid adhesive bandages invented by employee Earle Dickson and introduced to the market |
| 1932 | Robert Wood Johnson II becomes chairman; establishes decentralized management model |
| 1943 | Our Credo written by Robert Wood Johnson II |
| September 24, 1944 | IPO on the New York Stock Exchange, ticker JNJ |
| 1959 | McNeil Laboratories acquired, bringing the Tylenol brand into the J&J portfolio |
| 1961 | Janssen Pharmaceutica acquired; the Belgium-based pharmaceutical company was founded by Paul Janssen |
| September to October 1982 | Tylenol tampering crisis: seven deaths in Chicago from cyanide-laced capsules; J&J recalls approximately 31 million bottles and pioneers triple-seal tamper-resistant packaging |
| 1989 | Neutrogena skin care company acquired |
| 1998 | DePuy orthopaedics acquired |
| 2001 | Centocor acquired, adding Remicade (infliximab) to the pharmaceutical portfolio |
| 2011 | Synthes acquired for approximately $21.3 billion, the largest acquisition in J&J history at that time |
| 2017 | Actelion acquired for approximately $30 billion, adding rare disease and pulmonary arterial hypertension treatments |
| 2019 | Abiomed acquired for approximately $16.6 billion, adding heart pump devices to the medical device segment |
| May 2023 | Kenvue IPO: J&J spins off its consumer health segment (Band-Aid, Tylenol, Listerine, Neutrogena) as an independent publicly traded company |
| 2024 | Shockwave Medical acquired for approximately $13.1 billion, adding intravascular lithotripsy cardiovascular technology |
CEO timeline
| CEO | Tenure | Notable context |
|---|---|---|
| Robert Wood Johnson I | 1886 to 1910 | Co-founder; established the company's medical products focus |
| James Wood Johnson | 1910 to 1932 | Co-founder; oversaw early 20th-century growth |
| Robert Wood Johnson II | 1932 to 1963 | Wrote Our Credo (1943); established decentralized management; led NYSE listing (1944) |
| Philip Hofmann | 1963 to 1973 | First non-family CEO |
| Richard Sellars | 1973 to 1976 | |
| James Burke | 1976 to 1989 | Led the 1982 Tylenol crisis response; widely credited with preserving the brand |
| Ralph Larsen | 1989 to 2002 | Oversaw acquisition of Neutrogena and expansion of pharmaceutical portfolio |
| William Weldon | 2002 to 2012 | Oversaw Centocor integration and growth of the biologics portfolio |
| Alex Gorsky | 2012 to 2022 | Led Synthes, Actelion, and Abiomed acquisitions |
| Joaquin Duato | 2022 to present | Led Kenvue spin-off (2023) and Shockwave Medical acquisition (2024) |
Four eras of J&J history
Founding and consumer health era (1886 to 1944)
J&J's first six decades were defined by the antiseptic surgical products that gave rise to the company, followed by the expansion into consumer health with baby powder and Band-Aid. Robert Wood Johnson I built the company around the principles of Joseph Lister's germ theory at a time when hospitals routinely operated under non-sterile conditions. Distributing medical education materials directly to physicians positioned J&J as a trusted partner to the medical community rather than simply a product supplier. The Band-Aid, invented in 1921 by Earle Dickson for his wife, shifted the company toward consumer retail alongside its professional health presence. Under Robert Wood Johnson II, the decentralized operating model took shape, and Our Credo established the values framework that would be tested most acutely four decades later. The 1944 NYSE IPO opened the company to public investment for the first time, nearly 60 years after its founding.
Pharmaceutical and international expansion (1944 to 1982)
The decades following the IPO saw J&J expand from consumer and professional health products into pharmaceuticals through acquisition. The 1959 acquisition of McNeil Laboratories brought Tylenol into the portfolio. The 1961 acquisition of Janssen Pharmaceutica, founded by Belgian scientist Paul Janssen, gave J&J a European pharmaceutical research base with a track record of novel drug discovery. J&J grew internationally, establishing operations across multiple continents and building out the three-segment structure of consumer, pharmaceutical, and medical device businesses that would define the company for decades. By 1982, Tylenol had become the leading over-the-counter pain reliever in the United States, making up a substantial portion of J&J's consumer revenue.
Crisis response and pharmaceutical leadership (1982 to 2011)
The 1982 Tylenol tampering crisis tested J&J's crisis management framework in a nationally visible way. Seven people in the Chicago area died from Tylenol capsules laced with cyanide by an unknown individual. Under CEO James Burke, J&J pulled approximately 31 million bottles from retail shelves without waiting for government instruction, halted all Tylenol advertising, and worked with regulators to develop triple-seal tamper-resistant packaging that subsequently became an industry standard. The speed of the recall and the company's transparent public communication are credited with preserving consumer trust in the Tylenol brand, which recovered its market position within a year. Business schools continue to cite the 1982 J&J response as a reference case for handling product safety emergencies.
Subsequent decades brought further pharmaceutical growth. The 2001 acquisition of Centocor added Remicade (infliximab), a biologic treatment for autoimmune conditions including rheumatoid arthritis and Crohn's disease. The 2011 acquisition of Synthes for approximately $21.3 billion was the largest in J&J history at that time, substantially expanding the medical device segment into orthopedic trauma, spine, and cranio-maxillofacial implants.
Restructuring and focused strategy (2011 to present)
The final era of J&J history in this record has been defined by large acquisitions followed by a strategic decision to separate the consumer health segment. The 2017 acquisition of Actelion for approximately $30 billion added pulmonary arterial hypertension and other rare disease treatments. The 2019 acquisition of Abiomed for approximately $16.6 billion expanded J&J's cardiovascular device presence into heart pump technology. Under Joaquin Duato, who became CEO in January 2022, J&J concluded that the consumer health business had different growth drivers and capital needs than the pharmaceutical and medical device segments. The May 2023 Kenvue IPO separated consumer brands including Band-Aid, Tylenol, Listerine, and Neutrogena into an independent publicly traded company. J&J retained its pharmaceutical and MedTech segments, which carry higher margins and greater research and development intensity. The 2024 acquisition of Shockwave Medical for approximately $13.1 billion added intravascular lithotripsy technology for treating calcified cardiovascular lesions.
Johnson & Johnson (JNJ) dossier
Frequently Asked Questions
When was Johnson & Johnson founded?
Johnson & Johnson was founded in 1886 in New Brunswick, New Jersey, by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson. The company was incorporated in New Jersey in 1887. It was established to manufacture sterile surgical dressings and antiseptic products, inspired by British surgeon Joseph Lister's germ theory of infection.
When did Johnson & Johnson go public?
Johnson & Johnson completed its initial public offering on September 24, 1944, listing on the New York Stock Exchange under the ticker JNJ. Prior to the IPO, the company had operated as a privately held family business for nearly six decades.
What happened during the 1982 Tylenol crisis?
In September and October 1982, seven people in the Chicago area died after taking Tylenol capsules that had been laced with cyanide. Johnson & Johnson responded by recalling approximately 31 million bottles of Tylenol from store shelves and halting all advertising for the product. The company then reintroduced Tylenol in new triple-seal tamper-resistant packaging, which became an industry standard. The J&J response is widely studied in business schools as a benchmark for crisis management because the company prioritized consumer safety over short-term financial concerns.
What is the Johnson & Johnson Credo?
The Johnson & Johnson Credo is a statement of corporate values written by Robert Wood Johnson II in 1943, the year before the company's NYSE IPO. It lists the company's responsibilities in order: first to patients, doctors, nurses, and consumers; second to employees; third to communities; and fourth to stockholders. The Credo is credited with guiding management decisions including the 1982 Tylenol recall. It remains in use as a foundational policy document.
Why did Johnson & Johnson spin off Kenvue in 2023?
Johnson & Johnson separated its consumer health segment into an independent publicly traded company called Kenvue in May 2023. The spin-off allowed J&J to focus on its pharmaceutical and medical device businesses, which carry higher margins and growth potential than consumer brands. Kenvue took ownership of iconic products including Band-Aid, Tylenol, Listerine, and Neutrogena. The separation was structured as an IPO of Kenvue shares followed by an exchange offer to J&J shareholders.